Abstract:
The average lifespan of people suffering from HIV-AIDS is estimated to be 9 to 11 years, with
Vitamin D deciency as one of the most common phenomena among them. Anti-Retroviral
Therapy (ART) could signicantly enhance the quality of life of HIV-AIDS patients; however, it
further decreases Vitamin D serum levels among them. Objectives: To evaluate the impact of
vitamin D supplementation on immune function, viral load, and other health outcomes in HIVpositive
individuals. Methods: This was a descriptive study conducted on a sample of 95 HIVdiagnosed
patients aged 19 to 50 years in Punjab, Pakistan. Patients were selected from an AIDS
control clinic and prescribed antiretroviral therapy. Baseline assessments were conducted
using a structured evaluation questionnaire, and biochemical results were used to classify
vitamin D deciency. Results: The study presents information on PCR viral load counts in HIV
patients, including minimum (50), and maximum (750,000) values, mean (32,475) with standard
deviation (155,343), 5% sheared mean (28), and the 95% condence interval (17,802 to 47,148) for
the average. Results showed that HIV-positive patients taking vitamin D supplementation had a
lower mean rank (50.07) compared to those not taking supplements (57.00), with a difference of
275.5 in the sum of ranks between the two groups. Inferential statistics suggested that vitamin D
plays a signicant role in improving the prognosis of HIV patients taking ART, with a signicance
value of 0.0032. Conclusion: The present study concludes that Vitamin D supplementation has
a signicant role in improving the life status of HIV patients.
